Precil Varghese
Overview
Explore the profile of Precil Varghese including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
191
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mullerova H, Marshall J, De Nigris E, Varghese P, Pooley N, Embleton N, et al.
Ther Adv Respir Dis
. 2022 Jul;
16:17534666221113647.
PMID: 35894441
Background: The majority of patients with chronic obstructive pulmonary disease (COPD) suffer from comorbid cardiovascular (CV) disease. Accumulating evidence suggests a temporal association between COPD exacerbations and acute CV events,...
2.
Whittaker H, Rubino A, Mullerova H, Morris T, Varghese P, Xu Y, et al.
Int J Chron Obstruct Pulmon Dis
. 2022 Mar;
17:427-437.
PMID: 35264849
Background: Studies have shown that chronic obstructive pulmonary disease (COPD) exacerbation events are related to future events; however, previous literature typically reports frequent vs infrequent exacerbations per patient-year and no...
3.
Hurst J, Siddiqui M, Singh B, Varghese P, Holmgren U, De Nigris E
Int J Chron Obstruct Pulmon Dis
. 2021 May;
16:1303-1314.
PMID: 34007170
Background: Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality worldwide, causing substantial economic and social burden. Objective: This review assessed the patient-reported humanistic burden associated...
4.
Quint J, Venerus A, OLeary C, Myland M, Holmgren U, Varghese P, et al.
Int J Chron Obstruct Pulmon Dis
. 2020 Dec;
15:3261-3271.
PMID: 33324049
Purpose: Treatment guidance for chronic obstructive pulmonary disease (COPD) recommends inhaled corticosteroid (ICS)+long-acting muscarinic antagonist+long-acting β-agonist (LABA) triple therapy for patients who experience recurrent exacerbations, persistent breathlessness, or exercise limitation...
5.
Quint J, OLeary C, Venerus A, Holmgren U, Varghese P, Cabrera C
Pulm Ther
. 2020 Dec;
7(1):119-132.
PMID: 33284385
Introduction: Outcomes in chronic obstructive pulmonary disease (COPD) such as symptoms, hospitalisations and mortality rise with increasing disease severity. However, the heterogeneity of electronic medical records presents a significant challenge...
6.
Quint J, OLeary C, Venerus A, Myland M, Holmgren U, Varghese P, et al.
Pulm Ther
. 2020 Oct;
6(2):333-350.
PMID: 33064273
Introduction: Maintenance treatment strategies in COPD recommend inhaled corticosteroid (ICS) + long-acting muscarinic antagonist (LAMA) + long-acting β-agonist (LABA) triple therapy after initial dual therapy. Little is known about how...
7.
Hurst J, Skolnik N, Hansen G, Anzueto A, Donaldson G, Dransfield M, et al.
Eur J Intern Med
. 2020 Jan;
73:1-6.
PMID: 31954592
Exacerbations of chronic obstructive pulmonary disease (COPD) represent a significant clinical problem, and are associated with decreased lung function, worsening quality of life and decreased physical activity levels, with even...
8.
Varghese P, Gleason V, Sorokin R, Senholzi C, Jabbour S, Gottlieb J
J Hosp Med
. 2007 Aug;
2(4):234-40.
PMID: 17702035
Objective: To determine the incidence and manifestations of hypoglycemia in hospitalized patients receiving antihyperglycemic therapy. Research Design And Methods: The study was a 3-month prospective review of consecutive medical records...